This is a plain language summary of a clinical research study called RAPID. The study looked at the potential for how safe and effective etripamil was at stopping an episode of rapid heartbeats in people with atrioventricular-nodal-dependent supraventricular tachycardia (AV-node-dependent SVT). An episode is used to describe the period of time when a person experiences an abnormally very fast heartbeat. This was done by comparing an investigational drug called etripamil with a placebo, each administered via a rapidly acting nasal spray.This Plain Language Summary of Publication article (PLSP) from Future Cardiology looks at the results of a study called RAPID. AV-node-dependent SVT is a condition that affects the rhythm of the heart which, can cause it to suddenly beat rapidly.  The RAPID study examined the potential of a medication called etripamil, in stopping an episode of rapid heartbeats in people with AV-node-dependent SVT.

Visit the Future Medicine using the link to read the article.

This PLSP is based on an original article called ‘Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial’ and was published in The Lancet.

Visit The Lancet using the link to read the article.